Tpharm.info


Zolpidem safety





Zolpidem Containing Products Drug Safety Communication - FDA

12/25/2014
08:18 | Author: Emma Coleman

Zolpidem oral spray
Zolpidem Containing Products Drug Safety Communication - FDA

UPDATED 05/14/2013. FDA has approved label changes specifying new dosing recommendations for zolpidem products.

Including Ambien, Ambien CR, Edluar, and Zolpimist.

BACKGROUND : Zolpidem is a sedative-hypnotic (sleep) medicine used in adults for the treatment of insomnia.

Comments (1)Read more



The safety and tolerability of zolpidem--an update

10/24/2014
06:24 | Author: Lauren Ross

Zolpidem oral spray
The safety and tolerability of zolpidem--an update

The safety and tolerability of zolpidem--an update. Darcourt G, Pringuey D, Sallière D, Lavoisy J. Zolpidem belongs to a new class of hypnotic agents, chemically.

Generate a file for use with external citation management software.

Zolpidem belongs to a new class of hypnotic agents, chemically distinct from the pre-existing ones, and has a unique neuropharmacological profile. It induces sedative/hypnotic effects in rodents at doses much lower than those for anticonvulsant and myorelaxant activities. Clinically, zolpidem is indicated for the short term treatment of insomnia. It has a short half-life (2.4h), with no active metabolite, and does not accumulate during repeated administration. The pharmacokinetic profile associated with the absence of active metabolites is consistent with the short duration of action and absence of residual effects that have been observed. Polysomnographic experience indicates that zolpidem induces a sleep pattern which is similar to that of physiological sleep, and which produces either no or only minimal effects on sleep architecture after abrupt discontinuation. Aspects of the general safety of zolpidem have been studied in data obtained from healthy volunteers and patients, both adult and elderly, during its clinical development and in post-marketing experience. Zolpidem appears to be well-tolerated in adults and in the elderly, when administered in accordance with prescribing instructions. The available data indicate that, in these circumstances, the risk of abuse or dependence is minimal.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

Warning: The NCBI web site requires JavaScript to function. more.

Comments (0)

Zolpidem risk of drowsiness and reduced driving ability MHRA

8/23/2014
04:14 | Author: Emma Coleman

Zolpidem oral spray
Zolpidem risk of drowsiness and reduced driving ability MHRA

Taking zolpidem is associated with a risk of impaired driving ability the Article citation: Drug Safety Update volume 7 issue 10, May 2014: S1.

Home Safety information Drug Safety Update.

In Safety information.

Volume 7, Issue 10 May 2014.

Related Drug Safety Update articles.

European Medicines Agency announcement.

Zolpidem (Edluar, Stilnoct) is used to treat insomnia. Taking zolpidem is associated with a risk of impaired driving ability the next day. To reduce this risk, advise patients:

Advice to give to patients (106Kb).

Head office : 151 Buckingham Palace Road, Victoria, London, SW1W 9SZ General enquiries: To contact us about this website, use our feedback form.

People with liver impairment and the elderly should take no more than 5 milligrams of zolpidem a night. Further information.

Article citation: Drug Safety Update volume 7 issue 10, May 2014: S1.

Comments (0)

Zolpidem Safety Tip Smartmoves

6/22/2014
02:32 | Author: David Perry

Zolpidem oral spray
Zolpidem Safety Tip Smartmoves

Zolpidem Safety Tip. New lower recommended dosages from the Food and Drug Administration. The federal Food and Drug Administration (FDA) has.

The federal Food and Drug Administration (FDA) has recommended lower dosages of a sleep agent called zolpidem (brand name: Ambien) for patients using this drug. The dosing recommendations for zolpidem now call for a maximum dosage of 6.25 mg for women. Women do not break down the drug as quickly as men do, and have a much greater chance of being groggy and not alert in the morning, which can affect activities such as driving. The FDA suggests lower doses for men, too. All patients should be aware of the risks of impaired mental alertness the morning after taking zolpidem.

Current Size: 100%

Always discuss any changes in medications with your provider or pharmacist before decreasing or stopping any medications.

Comments (0)

Efficacy and Safety of Zolpidem Extended Release in Elderly

4/21/2014
12:30 | Author: David Perry

Zolpidem sanofi
Efficacy and Safety of Zolpidem Extended Release in Elderly

Objectives. To evaluate the clinical efficacy and safety of zolpidem extended release for the treatment of primary insomnia in elderly patients.

Comments (0)